
Over a Dozen FDA Approvals in 2024 Changed the Lung Cancer Field
It was a particularly eventful year in the non–small cell lung cancer (NSCLC) field with 11 FDA approvals, but that wasn't all in the lung cancer space. The regulatory body greenlit 2 agents for patients with small cell lung cancer (SCLC) and 1 regimen …